Change of Registered Office and Principal Place of Business
Released
Released
Announcement PDF
ABN 16 165 160 841
ASX RELEASE
1 August 2025
Change of Registered Office and Principal Place of Business
Amplia Therapeutics Limited (“ATX” or “the Company”) advises that it has today changed its Registered
Office and Principal Place of Business to:
Level 5, 90 William Street
Melbourne VIC 3000.
- End This ASX announcement was approved and authorised for release by the Company Secretary.
Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com
Media Contact:
H^CK Director, Haley Chartres
haley@hck.digital
+61 423 139 163
About Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal
Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the
field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic
and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic
pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter
(@ampliatx) and LinkedIn.
Level 5, 90 William Street, Melbourne VIC 3000
Email info@ampliatx.com Tel: +61 (0)3 9123 1140
www.ampliatx.com
Share your feedback
Discover